These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
22. Cabergoline for the prevention of ovarian hyperstimulation syndrome: systematic review and meta-analysis of randomized controlled trials. Leitao VM; Moroni RM; Seko LM; Nastri CO; Martins WP Fertil Steril; 2014 Mar; 101(3):664-75. PubMed ID: 24360566 [TBL] [Abstract][Full Text] [Related]
23. Dopamine agonist bromocriptine for the prevention of ovarian hyperstimulation syndrome. Spitzer D; Wogatzky J; Murtinger M; Zech MH; Haidbauer R; Zech NH Fertil Steril; 2011 Jun; 95(8):2742-4.e1. PubMed ID: 21411081 [TBL] [Abstract][Full Text] [Related]
24. Prevention of ovarian hyperstimulation syndrome in GnRH agonist IVF cycles in moderate risk patients: randomized study comparing hydroxyethyl starch versus cabergoline and hydroxyethyl starch. Matorras R; Andrés M; Mendoza R; Prieto B; Pijoan JI; Expósito A Eur J Obstet Gynecol Reprod Biol; 2013 Oct; 170(2):439-43. PubMed ID: 23932181 [TBL] [Abstract][Full Text] [Related]
25. Prevention of the onset of ovarian hyperstimulation syndrome (OHSS) in the rat after ovulation induction with a low molecular weight agonist of the LH receptor compared with hCG and rec-LH. van de Lagemaat R; Raafs BC; van Koppen C; Timmers CM; Mulders SM; Hanssen RG Endocrinology; 2011 Nov; 152(11):4350-7. PubMed ID: 21896671 [TBL] [Abstract][Full Text] [Related]
27. Can dopamine agonist at a low dose reduce ovarian hyperstimulation syndrome in women at risk undergoing ICSI treatment cycles? A randomized controlled study. Shaltout A; Shohyab A; Youssef MA Eur J Obstet Gynecol Reprod Biol; 2012 Dec; 165(2):254-8. PubMed ID: 22948132 [TBL] [Abstract][Full Text] [Related]
28. Prevention and treatment of moderate and severe ovarian hyperstimulation syndrome: a guideline. ; Fertil Steril; 2016 Dec; 106(7):1634-1647. PubMed ID: 27678032 [TBL] [Abstract][Full Text] [Related]
29. Whether Letrozole could reduce the incidence of early ovary hyperstimulation syndrome after assisted reproductive technology? A systematic review and meta-analysis. Zhao J; Xu B; Huang X; Yan Y; Li Y Reprod Health; 2020 Nov; 17(1):181. PubMed ID: 33218353 [TBL] [Abstract][Full Text] [Related]
30. Effect of the oral contraceptive pill on patients undergoing controlled ovarian hyperstimulation. Frederick J; DaCosta V; Wynter S; Reid M; Frederick C; McKenzie C West Indian Med J; 2004 Jan; 53(1):39-43. PubMed ID: 15114893 [TBL] [Abstract][Full Text] [Related]
31. Can dopamine agonists reduce the incidence and severity of OHSS in IVF/ICSI treatment cycles? A systematic review and meta-analysis. Youssef MA; van Wely M; Hassan MA; Al-Inany HG; Mochtar M; Khattab S; van der Veen F Hum Reprod Update; 2010; 16(5):459-66. PubMed ID: 20354100 [TBL] [Abstract][Full Text] [Related]
32. Ovarian hyperstimulation syndrome: review and new classification criteria for reporting in clinical trials. Humaidan P; Nelson SM; Devroey P; Coddington CC; Schwartz LB; Gordon K; Frattarelli JL; Tarlatzis BC; Fatemi HM; Lutjen P; Stegmann BJ Hum Reprod; 2016 Sep; 31(9):1997-2004. PubMed ID: 27343272 [TBL] [Abstract][Full Text] [Related]
33. Early onset of cabergoline therapy for prophylaxis from ovarian hyperstimulation syndrome (OHSS): A potentially safer and more effective protocol. Gaafar S; El-Gezary D; El Maghraby HA Reprod Biol; 2019 Jun; 19(2):145-148. PubMed ID: 31133458 [TBL] [Abstract][Full Text] [Related]
34. Avoiding ovarian hyperstimulation syndrome with the use of gonadotropin-releasing hormone agonist trigger. Fatemi HM; Garcia-Velasco J Fertil Steril; 2015 Apr; 103(4):870-3. PubMed ID: 25724740 [TBL] [Abstract][Full Text] [Related]
35. Implantation is apparently unaffected by the dopamine agonist Cabergoline when administered to prevent ovarian hyperstimulation syndrome in women undergoing assisted reproduction treatment: a pilot study. Alvarez C; Alonso-Muriel I; García G; Crespo J; Bellver J; Simón C; Pellicer A Hum Reprod; 2007 Dec; 22(12):3210-4. PubMed ID: 17921134 [TBL] [Abstract][Full Text] [Related]
37. RANZCOG CREI Consensus Statement on treatment of Ovarian Hyperstimulation Syndrome. Kwik M; Karia S; Boothroyd C Aust N Z J Obstet Gynaecol; 2015 Oct; 55(5):413-9. PubMed ID: 26279582 [TBL] [Abstract][Full Text] [Related]
38. Severe ovarian hyperstimulation syndrome after combined GnRH-agonist and low-dose human chorionic gonadotropin trigger in a patient with a single kidney. Pereira N; Lekovich JP; Kligman I; Rosenwaks Z Gynecol Endocrinol; 2017 Aug; 33(8):593-597. PubMed ID: 28440686 [TBL] [Abstract][Full Text] [Related]
39. Review of the evidence base of strategies to prevent ovarian hyperstimulation syndrome. Mathur R; Kailasam C; Jenkins J Hum Fertil (Camb); 2007 Jun; 10(2):75-85. PubMed ID: 17564886 [TBL] [Abstract][Full Text] [Related]